WO2024003784 - COMPOSITION FOR PREVENTING AND TREATING NEURODEGENERATIVE DISEASES
National phase entry is expected:
Publication Number
WO/2024/003784
Publication Date
04.01.2024
International Application No.
PCT/IB2023/056712
International Filing Date
28.06.2023
Title **
[English]
COMPOSITION FOR PREVENTING AND TREATING NEURODEGENERATIVE DISEASES
[French]
COMPOSITION VISANT À PRÉVENIR ET À TRAITER LES MALADIES NEURODÉGÉNÉRATIVES
Applicants **
ARIBIO CO., LTD.
56, Dongpangyo-ro, Bundang-gu
Seongnam-si
Gyeonggi-do 13535, KR
Inventors
CHOUNG, Jai Jun
234 Hwangsaeul-ro 229 ho, Bundang-gu
Seongnam-si
Gyeonggi-do, KR
KANG, Byungwoo
131 Namhangseo-ro 1 dong 2306 ho, Yeongdo-gu
Busan
Gyeongsangnam-do, KR
Priority Data
63/367,282
29.06.2022
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
MOIP
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 1122 | |
| EPO | Filing, Examination | 6692 | |
| Japan | Filing | 590 | |
| South Korea | Filing | 574 | |
| USA | Filing, Examination | 7510 |
Total: 16488 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
The present invention provides a composition for preventing or treating a neurodegenerative disease containing a phosphodiesterase 5 inhibitor (PDE5 inhibitor) and an N- methyl-D-aspartate-receptor(NMDA-receptor) antagonist and a method using thereof, wherein the PDE5 inhibitor is mirodenafil, sildenafil, vardenafil, tadalafil, udenafil, dasantafil, avanafil, pharmaceutically acceptable salts, solvates, hydrates, or a mixture thereof; and the NMDA- receptor antagonist is selected from among memantine, amantadine, ketamine, traxoprodil, lanicemine, rislenemdaz, pethidine, levorphanol, methadone, dextropropoxyphene, tramadol, ketobemidone, dextromethorphan (DXM), phencyclidine (PCP), and methoxetamine (MXE), pharmaceutically acceptable salts, solvates, hydrates and a mixture thereof.; and the neurodegenerative disease is dementia, Parkinson's disease (PD), Dementia with Lewy body (DEB), Alzheimer's disease (AD), Huntington's disease (HD), Multiple sclerosis (MS), Vascular Dementia (VaD), Amyotrophic Lateral Sclerosis (AES), frontotemporal dementia, or a mixed etiologies thereof.[French]
La présente invention concerne une composition pour prévenir ou traiter une maladie neurodégénérative contenant un inhibiteur de phosphodiestérase 5 (inhibiteur de PDE5) et un antagoniste du récepteur N-méthyl-D-aspartate (récepteur NMDA) et un procédé l'utilisant, l'inhibiteur de PDE5 étant le mirodénafil, le sildénafil, le vardénafil, le tadalafil, l'udénafil, le dasantafil, l'avanafil, des sels pharmaceutiquement acceptables, des solvates, des hydrates, ou un mélange de ceux-ci ; et l'antagoniste du récepteur NMDA étant choisi parmi la mémantine, l'amantadine, la kétamine, le traxoprodil, la lanicémine, la rislenemdaz, la péthidine, le lévorphanol, la méthadone, le dextropropoxyphène, le tramadol, la cétobémidone, le dextrométhorphane (DXM), la phéncyclidine (PCP) et la méthoxétamine (MXE), des sels pharmaceutiquement acceptables, des solvates, des hydrates et un mélange de ceux-ci ; et la maladie neurodégénérative étant la démence, la maladie de Parkinson (PD), la démence à corps de Lewy (DEB), la maladie d'Alzheimer (AD), la maladie de Huntington (HD), la sclérose en plaques (MS), la démence vasculaire (VaD), la sclérose latérale amyotrophique (AES), la démence frontotemporale, ou des étiologies mixtes de celles-ci.